Wall Street brokerages predict that Integra Lifesciences Holdings Corp (NASDAQ:IART) will report earnings of $0.65 per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Integra Lifesciences’ earnings. The highest EPS estimate is $0.67 and the lowest is $0.64. Integra Lifesciences reported earnings of $0.59 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 10.2%. The business is scheduled to report its next quarterly earnings report on Wednesday, October 30th.

According to Zacks, analysts expect that Integra Lifesciences will report full year earnings of $2.73 per share for the current financial year, with EPS estimates ranging from $2.70 to $2.75. For the next financial year, analysts expect that the firm will post earnings of $3.03 per share, with EPS estimates ranging from $2.95 to $3.09. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, July 24th. The life sciences company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.65 by $0.08. Integra Lifesciences had a net margin of 6.76% and a return on equity of 16.30%. The company had revenue of $383.60 million during the quarter, compared to analysts’ expectations of $373.29 million. During the same quarter in the previous year, the company earned $0.60 EPS. Integra Lifesciences’s revenue was up 4.8% on a year-over-year basis.

IART has been the topic of several recent analyst reports. BTIG Research set a $70.00 price objective on shares of Integra Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Zacks Investment Research raised shares of Integra Lifesciences from a “hold” rating to a “buy” rating and set a $65.00 price objective on the stock in a research note on Monday, September 2nd. BidaskClub lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 28th. ValuEngine lowered shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Finally, JMP Securities lifted their price target on shares of Integra Lifesciences to $75.00 in a research note on Thursday, July 25th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. Integra Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $62.42.

In related news, major shareholder Richard E. Caruso sold 520,000 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $60.97, for a total transaction of $31,704,400.00. Following the transaction, the insider now directly owns 134,134 shares in the company, valued at $8,178,149.98. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Lisa Evoli sold 2,380 shares of the business’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $63.00, for a total transaction of $149,940.00. Following the transaction, the insider now owns 2,588 shares in the company, valued at $163,044. The disclosure for this sale can be found here. In the last three months, insiders sold 887,921 shares of company stock worth $54,121,075. 4.50% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC acquired a new position in shares of Integra Lifesciences in the second quarter valued at $26,000. Stanley Laman Group Ltd. acquired a new position in shares of Integra Lifesciences in the first quarter valued at $223,000. Zions Bancorporation N.A. increased its holdings in shares of Integra Lifesciences by 5.9% in the second quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock valued at $243,000 after purchasing an additional 242 shares during the last quarter. Burney Co. acquired a new position in shares of Integra Lifesciences in the first quarter valued at $246,000. Finally, Cerebellum GP LLC acquired a new position in shares of Integra Lifesciences in the third quarter valued at $297,000. Institutional investors and hedge funds own 81.83% of the company’s stock.

Shares of NASDAQ:IART traded up $0.69 during trading on Wednesday, hitting $58.62. 10,847 shares of the company’s stock were exchanged, compared to its average volume of 453,893. The firm has a 50-day moving average price of $60.34 and a two-hundred day moving average price of $55.70. Integra Lifesciences has a 1-year low of $42.14 and a 1-year high of $65.09. The firm has a market cap of $5.14 billion, a P/E ratio of 24.26, a PEG ratio of 1.86 and a beta of 1.10. The company has a current ratio of 2.76, a quick ratio of 1.82 and a debt-to-equity ratio of 0.99.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: What is included in the gross domestic product?

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.